Pharmacokinetic and Safety Profile of the Novel HIV Non-Nucleoside Reverse Transcriptase Inhibitor MK-8507 in Adults without HIV,Antimicrobial Agents and Chemotherapy

当前位置： X-MOL 学术 › Antimicrob. Agents Chemother. › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

Pharmacokinetic and Safety Profile of the Novel HIV Non-Nucleoside Reverse Transcriptase Inhibitor MK-8507 in Adults without HIV
Antimicrobial Agents and Chemotherapy ( IF 4.9 ) Pub Date : 2021-09-13 , DOI: 10.1128/aac.00935-21
Wendy Ankrom ₁ , Deanne Jackson Rudd ₁ , Andrea Schaeffer ₁ , Deborah Panebianco ₁ , Evan J Friedman ₁ , Charles Tomek ₂ , S Aubrey Stoch ₁ , Marian Iwamoto ₁

Affiliation

MK-8507 is a novel HIV-1 non-nucleoside reverse transcriptase inhibitor in clinical development with potential for once-weekly oral administration for the treatment of HIV-1 infection. Two randomized, double-blind, placebo-controlled phase 1 studies in ...

中文翻译：